Barclays
BCRX icon

Barclays’s BioCryst Pharmaceuticals BCRX Stock Holding History

Barclays’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Sell
133,597
-592,770
-82% -$4.6M ﹤0.01% 2601
2025
Q4 		$5.67M Sell
726,367
-55,865
-7% -$404K ﹤0.01% 2120
2025
Q3 		$5.94M Sell
782,232
-21,880
-3% -$182K ﹤0.01% 2060
2025
Q2 		$7.2M Buy
804,112
+401,512
+100% +$3.74M ﹤0.01% 1812
2025
Q1 		$3.02M Sell
402,600
-61,646
-13% -$497K ﹤0.01% 2318
2024
Q4 		$3.49M Sell
464,246
-12,426
-3% -$94.3K ﹤0.01% 2459
2024
Q3 		$3.62M Buy
476,672
+250,086
+110% +$1.9M ﹤0.01% 2355
2024
Q2 		$1.4M Sell
226,586
-49,672
-18% -$274K ﹤0.01% 2385
2024
Q1 		$1.4M Sell
276,258
-428,271
-61% -$2.41M ﹤0.01% 2861
2023
Q4 		$4.22M Buy
704,529
+157,201
+29% +$911K ﹤0.01% 2255
2023
Q3 		$3.88M Sell
547,328
-2,411
-0.4% -$17.3K ﹤0.01% 1490
2023
Q2 		$3.87M Sell
549,739
-153,434
-22% -$1.23M ﹤0.01% 1494
2023
Q1 		$5.86M Buy
703,173
+218,681
+45% +$2.11M ﹤0.01% 1435
2022
Q4 		$5.56M Buy
484,492
+72,976
+18% +$910K ﹤0.01% 1547
2022
Q3 		$5.18M Buy
411,516
+324,633
+374% +$4.18M 0.01% 1141
2022
Q2 		$918K Sell
86,883
-35,444
-29% -$366K ﹤0.01% 2440
2022
Q1 		$1.99M Sell
122,327
-96,205
-44% -$1.54M ﹤0.01% 1867
2021
Q4 		$3.03M Buy
218,532
+139,616
+177% +$1.85M ﹤0.01% 2088
2021
Q3 		$1.13M Sell
78,916
-3,253
-4% -$51.3K ﹤0.01% 2714
2021
Q2 		$1.3M Sell
82,169
-153,124
-65% -$2.08M ﹤0.01% 2490
2021
Q1 		$2.39M Buy
235,293
+137,263
+140% +$1.42M ﹤0.01% 2114
2020
Q4 		$730K Sell
98,030
-189,675
-66% -$978K ﹤0.01% 2981
2020
Q3 		$987K Sell
287,705
-86,006
-23% -$369K ﹤0.01% 2708
2020
Q2 		$1.78M Sell
373,711
-775,135
-67% -$3.1M ﹤0.01% 2230
2020
Q1 		$2.3M Buy
1,148,846
+949,442
+476% +$2.61M ﹤0.01% 2164
2019
Q4 		$688K Sell
199,404
-33,802
-14% -$85K ﹤0.01% 4014
2019
Q3 		$669K Sell
233,206
-127,631
-35% -$397K ﹤0.01% 4003
2019
Q2 		$1.37M Buy
360,837
+255,012
+241% +$1.53M ﹤0.01% 3354
2019
Q1 		$861K Buy
105,825
+64,891
+159% +$556K ﹤0.01% 3569
2018
Q4 		$330K Sell
40,934
-4,214
-9% -$32.8K ﹤0.01% 4196
2018
Q3 		$345K Buy
45,148
+34,050
+307% +$229K ﹤0.01% 4573
2018
Q2 		$64K Sell
11,098
-18,376
-62% -$101K ﹤0.01% 5509
2018
Q1 		$140K Buy
29,474
+5,801
+25% +$29.8K ﹤0.01% 5125
2017
Q4 		$116K Buy
23,673
+8,778
+59% +$42.5K ﹤0.01% 5131
2017
Q3 		$78K Sell
14,895
-147,821
-91% -$757K ﹤0.01% 5095
2017
Q2 		$904K Buy
162,716
+138,029
+559% +$841K ﹤0.01% 2972
2017
Q1 		$208K Sell
24,687
-37,777
-60% -$263K ﹤0.01% 4278
2016
Q4 		$396K Buy
62,464
+61,050
+4,318% +$318K ﹤0.01% 3597
2016
Q3 		$7K Sell
1,414
-17,159
-92% -$68.5K ﹤0.01% 5902
2016
Q2 		$52K Sell
18,573
-2,095
-10% -$6.5K ﹤0.01% 4804
2016
Q1 		$41K Buy
20,668
+3,231
+19% +$14.3K ﹤0.01% 4880
2015
Q4 		$175K Sell
17,437
-63,280
-78% -$629K ﹤0.01% 4011
2015
Q3 		$887K Buy
80,717
+31,633
+64% +$422K ﹤0.01% 2840
2015
Q2 		$686K Buy
49,084
+45,902
+1,443% +$522K ﹤0.01% 3210
2015
Q1 		$29K Sell
3,182
-3,109
-49% -$32.2K ﹤0.01% 5623
2014
Q4 		$75K Sell
6,291
-4,817
-43% -$53.2K ﹤0.01% 5404
2014
Q3 		$100K Sell
11,108
-4,147
-27% -$50.8K ﹤0.01% 5326
2014
Q2 		$182K Buy
15,255
+4,915
+48% +$47.8K ﹤0.01% 4905
2014
Q1 		$103K Sell
10,340
-13,668
-57% -$146K ﹤0.01% 5429
2013
Q4 		$168K Sell
24,008
-2,082
-8% -$13.2K ﹤0.01% 5172
2013
Q3 		$183K Sell
26,090
-143,196
-85% -$726K ﹤0.01% 5131
2013
Q2 		$262K Buy
+169,286
New +$292K ﹤0.01% 4920

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Barclays's BCRX Position: Q1 2026 in Review

Barclays reduced its BioCryst Pharmaceuticals (BCRX) stake by 82% in Q1 2026, selling an estimated $4.6M and leaving 133,597 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Barclays first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.2M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Barclays held 133,597 shares of BioCryst Pharmaceuticals worth $1.27M as of Q1 2026.
  • Barclays sold 592,770 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $4.6M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2601 holding.
  • Barclays first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Barclays's BioCryst Pharmaceuticals position peaked at $7.2M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.